Related Experiment Video
Updated: May 19, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Diabetes pharmacotherapy in 2012: considerations in medication selection
Susan Cornell1, Vincent J Dorsey
1Midwestern University Chicago College of Pharmacy, Downers Grove, IL 60515, USA. scorne@midwestern.edu
Postgraduate Medicine
|August 24, 2012
Summary
Type 2 diabetes mellitus (T2DM) management is complex, with many patients failing to reach target blood glucose levels. Enhanced knowledge of T2DM pathophysiology, treatments, and guidelines is crucial for healthcare professionals.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Public Health
Background:
- Type 2 diabetes mellitus (T2DM) is a growing global health crisis.
- Effective management of T2DM is challenging, with less than 50% of patients achieving recommended glycated hemoglobin goals.
- Numerous barriers impede optimal blood glucose control in T2DM patients.
Purpose of the Study:
- To underscore the increasing complexity of T2DM therapy and management.
- To highlight the critical need for healthcare professionals to update their knowledge on T2DM.
- To emphasize the importance of understanding current pathophysiology, treatment options, and clinical guidelines for T2DM.
Main Methods:
- This study is a review and synthesis of current knowledge on T2DM.
- It analyzes patient- and clinician-determined barriers to achieving glycemic control.
- It emphasizes the need for enhanced knowledge of T2DM pathophysiology and management.
Main Results:
- The incidence of T2DM is rising epidemically worldwide.
- Suboptimal glycemic control persists in a significant portion of the T2DM population.
- Barriers to achieving target blood glucose levels are multifaceted.
Conclusions:
- Healthcare professionals require updated knowledge on T2DM pathophysiology, treatments, and guidelines.
- Addressing barriers is essential for improving T2DM management outcomes.
- Proactive management and enhanced clinical knowledge are vital for combating the T2DM epidemic.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...